Aberdeen lifts Sera Prognostics stake to 7.21% despite $14K quarterly revenue
What's the deal? Aberdeen GroupDealroom has a profile for this one. Try Dealroom → plc added to its holding in US women's health diagnostics company Sera Prognostics on June 30, 2026, buying 202,750 shares at $1.82 each. That lifted its total stake to 2,753,525 shares, or 7.21% of the company.
What does Sera do? The company develops blood-based biomarker tests and predictive analytics to improve maternal and neonatal care. Investor material describes it as a single operating segment.
The numbers: Sera's revenue reached just $14,000 in the quarter to March 31, 2026. Full-year 2025 revenue was $0.08 million, against a net loss of $31.93 million.
Its market value was reported at roughly $70.5 million to $88.9 million in late June and mid-July 2026, depending on the source and date, with shares trading well below their IPO-era level. Prices ranged from $1.79 on June 26 to $2.29 on July 22, per GuruFocus, which listed a GF Value estimate of $1.83.
Why the interest? Aberdeen holds the position with subsidiary abrdn Inc., which shares voting and dispositive power, inside a parent structure spanning Aberdeen Group plc and abrdn Holdings Limited. The firm's portfolio has long tilted towards large technology and healthcare names.
What could go wrong? The purchase backs a small-cap developer with weak profitability, negative cash flow and a thin revenue base. Sera's valuation, execution and path to scale remain under close scrutiny.
The signal: Analyst sentiment stays upbeat despite the turbulence. StockAnalysis, citing four analysts polled by S&P Global, reported a consensus Strong Buy rating and an average target of $5.50 — sizeable upside from current prices, and a sign that institutional money is still willing to bet on overlooked biotech.
Read more: Noah News
